Patents by Inventor Giacomo Paonessa

Giacomo Paonessa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10815222
    Abstract: The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions containing the compounds and their use in the treatment of kinetoplastid infections.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 27, 2020
    Assignee: C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Ilaria Biancofiore, Alina Ciammaichella, Federica Ferrigno, Steven Harper, Savina Malancona, Jesus Maria Ontoria Ontoria, Giacomo Paonessa, Simona Ponzi, Vincenzo Summa
  • Publication number: 20200095232
    Abstract: The present invention relates to a class of novel heterocyclic compounds, to pharmaceutical compositions containing the compounds and their use in the treatment of kinetoplastid infections.
    Type: Application
    Filed: December 21, 2017
    Publication date: March 26, 2020
    Applicant: C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Ilaria BIANCOFIORE, Alina CIAMMAICHELLA, Federica FERRIGNO, Steven HARPER, Savina MALANCONA, Jesus Maria ONTORIA ONTORIA, Giacomo PAONESSA, Simona PONZI, Vincenzo SUMMA
  • Publication number: 20170157102
    Abstract: The present invention relates to Perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of a pathology caused by trematodes.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Inventors: Giovina RUBERTI, Cristiana LALLI, Alessandra GUIDI, Alberto BRESCIANI, Nadia GENNARI, Giacomo PAONESSA, Emanuela NIZI
  • Patent number: 9365541
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 14, 2016
    Assignee: IRBM—SCIENCE PARK S.P.A.
    Inventors: Sergio Altamura, Ilaria Biancofiore, Alberto Bresciani, Federica Ferrigno, Steven Harper, Ralph Laufer, Jesus Maria Ontoria Ontoria, Savina Malancona, Edith Monteagudo, Emanuela Nizi, Maria Vittoria Orsale, Simona Ponzi, Giacomo Paonessa, Vincenzo Summa, Maria Veneziano
  • Publication number: 20150299163
    Abstract: The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as Plasmodium falciparum, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 22, 2015
    Applicants: IRBM - SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING
    Inventors: Sergio ALTAMURA, Ilaria BIANCOFIORE, Alberto BRESCIANI, Federica FERRIGNO, Steven HARPER, Ralph LAUFER, Jesus Maria ONTORIA ONTORIA, Savina MALANCONA, Edith MONTEAGUDO, Emanuela NIZI, Maria Vittoria ORSALE, Simona PONZI, Giacomo PAONESSA, Vincenzo SUMMA, Maria VENEZIANO
  • Patent number: 8198426
    Abstract: The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: June 12, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Giacomo Paonessa, Giovanni Migliaccio, Raffaele De Francesco
  • Publication number: 20070264674
    Abstract: A method for identifying compounds that can induce expression of cytochrome P450, in particular, expression of the CYP3A4 isoform, is described. The method provides a reporter gene operably linked to a composite promoter comprising in tandem one or more cis-acting elements, which are bound by activated pregnane X receptor (PXR), operably linked to a heterologous promoter. Analytes, which are inducers CYP3A4 expression via PXR activation, induce expression of the reporter gene.
    Type: Application
    Filed: August 15, 2005
    Publication date: November 15, 2007
    Inventors: Giacomo Paonessa, Sandra Cicuzza, Ralph Laufer
  • Publication number: 20050239205
    Abstract: The present invention features GBV-B replicons and replicon enhanced cells. A GBV-B replicon is an RNA molecule able to autonomously replicate in a cultured cell and produce detectable levels of one or more GBV-B proteins. GBV-B replicon enhanced cells are cells having an increased ability to maintain a GBV-B replicon.
    Type: Application
    Filed: January 13, 2003
    Publication date: October 27, 2005
    Inventors: Amedeo De Tomassi, Rita Graziani, Giacomo Paonessa, Cinzia Traboni
  • Publication number: 20040067486
    Abstract: The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.
    Type: Application
    Filed: July 21, 2003
    Publication date: April 8, 2004
    Inventors: Giacomo Paonessa, Giovanni Migliaccio, Raffaele De Francesco
  • Patent number: 6565869
    Abstract: The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated disease, for example hyperglycemia. FIG. 1 shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: May 20, 2003
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Gennaro Ciliberto, Patrizia Costa, Giacomo Paonessa, Domenico Lazzaro, Isabelle Gloaguen, Annalise Di Marco, Anna De Martis, Ralph Laufer, Riccardo Cortese
  • Patent number: 5972902
    Abstract: The present invention relates to human interleukin-6 receptor antagonists which are incapable of binding to the receptor chain responsible for transduction of the signal associated with interleukin-6, namely, gp130. The present invention also relates to DNA encoding human interleukin-6 receptor antagonists.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: October 26, 1999
    Inventors: Gennaro Ciliberto, Rocco Savino, Giacomo Paonessa